Tepotinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-TEPOTINIB |
|---|---|
| Type | Drug |
| Aliases | TepmetkoТепотініб |
| Status | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | MET-selective TKI |
|---|---|
| Mechanism | Selective MET inhibitor with similar efficacy profile to capmatinib. VISION trial: ORR ~46% in 1L MET ex14+ NSCLC. |
| Typical dosing | 450 mg PO once daily. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
Once-daily alternative to capmatinib BID. Edema dominant AE.
Used By
Regimens
REG-TEPOTINIB-NSCLC- Tepotinib monotherapy (VISION) — MET ex14 NSCLC